PMID- 23580323
OWN - NLM
STAT- MEDLINE
DCOM- 20131107
LR  - 20210816
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 133
IP  - 8
DP  - 2013 Oct 15
TI  - Prognostic and predictive value of estrogen receptor 1 expression in completely 
      resected non-small cell lung cancer.
PG  - 1825-31
LID - 10.1002/ijc.28209 [doi]
AB  - Adjuvant chemotherapy (ACT) leads to a modest improvement in survival among 
      patients with completely resected non-small cell lung cancer (NSCLC) but 
      molecular predictors are still rare. Publicly available gene microarray, clinical 
      and follow-up data from two different studies on early-stage NSCLC were used to 
      determine the expression of estrogen receptor 1 (ESR1). Expression values were 
      calculated against clinical and survival data in a training set (n = 138) and a 
      test set (subpopulation from the adjuvant JBR.10 study) allowing the 
      determination of the prognostic effect of ESR1 in the observational arm as well 
      as the predictive effect of ESR1 regarding ACT. Data were well balanced in terms 
      of ESR1 expression. ESR1 high expression was of significant positive prognostic 
      value in the training set and this could be confirmed in the test set cohort 
      (hazard ratio for overall survival 0.248, 95% confidence interval: 0.088-0.701; p 
      = 0.008). Additionally, ESR1 low tumors showed a benefit from ACT in terms of 
      5-year survival (33.3% observation arm and 77.8% ACT arm; p = 0.003), whereas 
      patients with ESR1 high tumors did not have any benefit from ACT (test of 
      interaction p = 0.024). ESR1 is an independent positive prognostic factor for 
      survival in early-stage NSCLC patients. Patients with ESR1 high tumors did not 
      benefit from ACT.
CI  - Copyright (c) 2013 UICC.
FAU - Brueckl, Wolfgang Michael
AU  - Brueckl WM
AD  - Department of Internal Medicine, 3, Klinikum Nurnberg, Nuremberg, Germany. 
      wolfgang.brueckl@klinikum-nuernberg.de
FAU - Al-Batran, Salah-Eddin
AU  - Al-Batran SE
FAU - Ficker, Joachim Hans
AU  - Ficker JH
FAU - Claas, Silke
AU  - Claas S
FAU - Atmaca, Akin
AU  - Atmaca A
FAU - Hartmann, Arndt
AU  - Hartmann A
FAU - Rieker, Ralf Joachim
AU  - Rieker RJ
FAU - Wirtz, Ralph Markus
AU  - Wirtz RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130507
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
SB  - IM
MH  - Biomarkers, Tumor
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/surgery
MH  - Chemotherapy, Adjuvant
MH  - Estrogen Receptor alpha/*metabolism
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/mortality/surgery
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adjuvant treatment
OT  - estrogen receptor 1 (ESR1)
OT  - gene expression
OT  - non-small cell lung cancer (NSCLC)
OT  - prognosis
EDAT- 2013/04/13 06:00
MHDA- 2013/11/08 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/10/25 00:00 [received]
PHST- 2013/03/25 00:00 [accepted]
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2013/11/08 06:00 [medline]
AID - 10.1002/ijc.28209 [doi]
PST - ppublish
SO  - Int J Cancer. 2013 Oct 15;133(8):1825-31. doi: 10.1002/ijc.28209. Epub 2013 May 
      7.